title: [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
abstract: Varicella is a highly contagious viral disease which mainly affects young children and usually is perceived as infection with a mild disease course. However, there is increasing evidence indicating that the morbidity and mortality as well as the economic impact associated with varicella are significant. While universal childhood vaccination against varicella is currently not recommended in Germany, the availability of safe and efficacious vaccines offers the opportunity for preventive intervention. Detailed and reliable data on the consequences of varicella and the possible impact of a universal vaccination program are missing to date for Germany. In order to generate this information, we conducted a comprehensive evaluation. The objective was to quantify the medical consequences and the economic impact of varicella on third-party payers and the society by means of a model analysis, and particularly to assess the effects of various universal vaccination strategies. The study confirms that varicella represents a significant health and economic burden in Germany. Following mathematical modelling, universal varicella vaccination for children at the age of 12-18 months could prevent more than 82 % of cases and complications on average per year. Economically, universal vaccination would lead to net cost savings not only for the society but also for the third-party payers. From these findings it can be concluded that universal varicella vaccination is a strategy which should be encouraged, from a medical, epidemiological, but also economic viewpoint.
authors.affiliation: Kinderklinik und Kinderpoliklinik, Johannes Gutenberg Universität, Langenbeckstrasse 1, 55101 Mainz. knuf@kinder.klinik.uni-mainz.de
authors.forename: M
authors.initials: M
authors.lastname: Knuf
authors.forename: A
authors.initials: A
authors.lastname: Neiss
authors.forename: P
authors.initials: P
authors.lastname: Wutzler
mesh_terms: D002644:Chickenpox / Q000150:complications / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D019433:Chickenpox Vaccine / Q000008:administration & dosage* / Q000191:economics*; D002648:Child; D002675:Child, Preschool; D003198:Computer Simulation; D017046:Cost Savings / Q000191:economics; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D005858:Germany; D006801:Humans; D007223:Infant; D018803:Models, Economic; D009313:National Health Programs / Q000191:economics*; D014611:Vaccination / Q000191:economics*
chemical_list: D019433:Chickenpox Vaccine